PRD_000204

Vancomycin

PRD_000204 is described in the Biologically Interesting Molecule Reference Dictionary (BIRD).

The representative PDB ID is 1AA5.

Find entries where PRD_000204 is present

Chemical Component Summary
Name	Vancomycin
Identifiers	n/a
Formula	C₆₆ H₇₅ Cl₂ N₉ O₂₄
Molecular Weight	1,449.254
Type	PEPTIDE-LIKE
Isomeric SMILES	C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2Oc3c4cc5cc3Oc6ccc(cc6Cl)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7c8ccc(c(c8)-c9c(cc(cc9O)O)[C@H](NC(=O)[C@H]([C@@H](c1ccc(c(c1)Cl)O4)O)NC7=O)C(=O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)CO)O)O)(C)N)O
InChI	InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
InChIKey	MYPYJXKWCTUITO-LYRMYLQWSA-N
Composition	Polymer Sequences: MLU-OMZ-ASN-GHP-GHP-OMY-3FG-BGC-RER
BIRD class	ANTIBIOTIC
Represented As	POLYMER
Compound Details	n/a
Description	n/a

Chemical Details
Formal Charge	0
Atom Count	176
Chiral Atom Count	18
Bond Count	185
Aromatic Bond Count	30

Drug Info: DrugBank

DrugBank ID	DB00512
Name	Vancomycin
Groups	approved
Description	Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by _Staphylococcus aureus_, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make _Clostridium difficile_ associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].
Synonyms	Vancomycinum Vancomycin hydrochloride Vancomycine Vancomicina Vancomycin
Brand Names	Firvanq PMS-vancomycin 1 G Vancomycin HCl Vancomycin Hydrochloride Capsules, USP Sterile Vancomycin HCl USP 500mg/vial Vancomycin Injection USP In 0.9% Sodium Chloride Jamp Vancomycin Vancomycin Vancocin Cp Add-vantage Inj 500mg/vial Vancomycin Hydrochloride Sterile Vancomycin Hydrochloride Sterile Vancomycin HCl 5.0gm/vial Sterile Vancomycin Hydrochloride, USP Vancomycin hydrochloride Jamp-vancomycin Vancomycin Hydrochloride for Injection Vancocin PMS-vancomycin PMS-vancomycin 500 mg Vancomycin Hydrocloride Vancocin Inj 1gm/vial Advantage Pmsc-vancomycin Vancomycin Hydrochloride for Injection USP Sterile Vancomycin HCl USP 1.0gm/vial Vancomycin Hydrochloride for Oral Solution Vancomycin Hydrochloride for Injection, USP Vancomycin Injection USP In 5% Dextrose
Indication	Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections.[L41529] Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of _Clostridium difficile_-associated diarrhea and for enterocolitis caused by _Staphylococcus aureus_ (including methicillin-resistant strains).[L41534]
Categories	Agents that produce neuromuscular block (indirect) Alimentary Tract and Metabolism Amino Acids, Peptides, and Proteins Anti-Bacterial Agents Anti-Infective Agents Antibacterials for Systemic Use Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents Antiinfectives for Systemic Use Carbohydrates Drugs that are Mainly Renally Excreted Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index Glycoconjugates Glycopeptide Antibacterials Glycopeptides Intestinal Antiinfectives Narrow Therapeutic Index Drugs Nephrotoxic agents Ophthalmologicals Peptides Sensory Organs
ATC-Code	J01XA01 A07AA09 S01AA28
CAS number	1404-90-6

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan	-	unknown	ligand
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	substrate
alpha1-acid glycoprotein	MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAF...	unknown	substrate
Histamine H1 receptor	MSLPNTSSASEDKMCEGNRTAMASPQLLPLVVVLSSISLVTVGLNLLVLY...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682